PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTX) (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell ...
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients Clinical benefit observed in 83% of evaluable patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results